A role for androgen receptor variant 7 in sensitivity to therapy: Involvement of IGFBP-2 and FOXA1.

Biernacka, K M; Barker, R; Sewell, A; Bahl, A; Perks, C M

Biernacka, K M; Barker, R; Sewell, A; Bahl, A; Perks, C M.

Afiliación

Biernacka KM; Cancer Endocrinology Group, Translational Health Sciences, University of Bristol Southmead Hospital, BS10 5NB, Bristol, UK.
Barker R; Cancer Endocrinology Group, Translational Health Sciences, University of Bristol Southmead Hospital, BS10 5NB, Bristol, UK.
Sewell A; Department of Cellular Pathology, North Bristol NHS Trust, Southmead Hospital, Bristol, UK.
Bahl A; Bristol Haematology and Oncology Centre, Department of Clinical Oncology, University Hospitals Bristol, Bristol BS2 8ED, UK.
Perks CM; Cancer Endocrinology Group, Translational Health Sciences, University of Bristol Southmead Hospital, BS10 5NB, Bristol, UK. Electronic address: claire.m.perks@bristol.ac.uk.

Transl Oncol ; 34: 101698, 2023 Aug.

Article en En | MEDLINE | ID: mdl-37307644

Palabras clave

ARV7; Androgen receptor; Chemotherapy; FOXA1; IGFBP-2; Prostate cancer

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Tipo de estudio: Diagnostic_studies Idioma: En Revista: Transl Oncol Año: 2023 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google